Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: Preliminary study

International Angiology

Volumn 27, Issue 4, 2008, Pages 296-301

  Gosk Bierska, Iza ^a   Wysokinski W ^b   Karnicki, K ^b   Adamiec, R ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b MAYO CLINIC   (United States)

Author keywords

Arterial occlusive diseases; Atherosclerosis; Lipoprotein associated coagulation inhibitor; Thromboplastin

Indexed keywords

FIBRINOGEN; THROMBOPLASTIN; TISSUE PATHWAY FACTOR INHIBITOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD SAMPLING; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERMITTENT CLAUDICATION; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN BLOOD LEVEL; RISK FACTOR; SMOKING HABIT;

ARTERIAL OCCLUSIVE DISEASES; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD COAGULATION; CASE-CONTROL STUDIES; FEMALE; HUMANS; ISCHEMIA; LIPOPROTEINS; LOWER EXTREMITY; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PILOT PROJECTS; RISK ASSESSMENT; RISK FACTORS; THROMBOPLASTIN; UP-REGULATION;

EID: 50049123321     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1-8.
2. Giensen PL, Rauch U, Borhmann B, Kling D, Roque M, Fallon J et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999;96:2311-5.
3. Rauch U, Nemerson Y. Circulating tissue factor and thrombosis. Curr Opin Hematol 2000;7:273-7.
4. Celi A, Pellegrini B, Lorenzet R, De Blasi A, Ready N, Furie BC et al. P-selectin induces the expression of t factor on monocytes. Proc Natl Acad Sci U S A 1994;91:8767-71.
5. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004;24:1015-22.
6. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997;95:594-9.
7. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease. Thromb Haemost 1998;79:495-9.
8. Soejima H, Ogawa H, Yasue H, Suefuji H, Kaikita K, Tsuji I et al. Effects of enalapril on tissue factor in patients with uncomplicated acute myocardial infarction. Am J Cardiol 1996;78:336-40.
9. Suefuji H, Ogawa H, Yasue H, Hirofumi M, Kaikita K, Soejima H et al. Increased plasma tissue factor levels in acute myocardial interaction. Am Heart J 1997;134:253-9.
10. Caplice NM, Mueske CS, Kleppe LS, Peterson TE, Bronze GJ, Simari RD. Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors. Circ Res 1998;83:1264-70.
11. Peti L, Lenik, Dachet C, Moreau M, Champan J. Tissue factor pathway inhibitor is expressed by human monocyte-derived macrophages: relationship to tissue factor induction by cholesterol and oxidized LDL. Arterioscler Thromb Vasc Biol 1999;19:309-15.
12. Yamabe H, Osawa H, Inuma H, Kaizuka M, Tamura N, Tsunoda S et al. Tissue factor pathway inhibitor production by human mesangial cells in culture. Thromb Haemost 1996;76:215-9.
13. Bara L, Bloch MF, Zitoun D, Samama M, Collignon F, Frydman A et al. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombotic consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Clinical trial. Thromb Res 1993;69:443-52.
14. Sandset PM, Abilgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988;50:803-13.
15. Broze GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990;29:7539-46.
16. Hamik A, Setiadi H, Bu G, McEver RP, Morrissey JH. Down-regulation of monocyte tissue factor-mediated by TFPI and LRP. J Biol Chem 1999;274:4962-9.
17. Broze GJ, Lange GW, Duffin KL, MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1994;5:551-9.
18. Kamikura Y, Wada H, Yamada A, Shimura M, Hiyoyama K, Shiku H et al. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Haematol 1997;55:183-7.
19. Soejima H, Ogawa H, Yasue H, Suefuji H, Kaikita K, Nishiyama K et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999;99:2908-13.
20. Gosk-Bierska I, Adamiec R, Alexewicz P, Wysokinski E. Coagulation in diabetic and non-diabetic claudicants. Int Angiol 2002;21:128-33.
21. Gosk-Bierska I, Adamiec R, Wysokinski WE. Plasmin-alpha2-antiplasmin complexes in diabetic and non-diabetic patients with peripheral arterial occlusive disease. J Thromb Haemost 2003;1 Suppl 1:961.
22. Blann A, Amiral J, Mc Collum Ch, Lip G. Differences in free and total tissue factor pathway inhibitor and tissue factor in peripheral artery disease compared to healthy controls. Atherosclerosis 2000;152:29-34.
23. Nordfang O, Bjorn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC et al. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 1991;30:10371-6.
24. Wesselschmidt R, Likert KM, Girard TJ, Wun TC, Bronze GJ. Tissue factor pathway inhibitor the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992;79:2004-10.
25. Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordy A. Tissue factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 1994;14:223-9.
26. Ettelaie C, Wilbourn BR, Adam J, James NJ, Bruckdorfer KR. Comparison of the inhibitory effects of apoB100 and tissue factor pathway inhibitor on tissue factor and the influence of lipoprotein oxidation. Arterioscler Thromb Vasc Biol 1999;19:1784-90.
27. Mast AE, Bronze GJ Jr. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood 1996;87:1845-50.
28. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999;26:348-53.
29. Annex BH, Denning SM, Channon KM, Sketch MH, Stack RS, Morrissey JH et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995;91:619-22.
30. Saito Y, Wada H, Yamamuro M, Inoue A, Shimura M, Hiyoyama K et al. Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease. Am J Hematol 1999;61:238-42.
31. Golino P, Ravera A, Ragini M, Cirillo P, Piro O, Chiariello M. Involvement of tissue factor and tissue factor pathway inhibitor in coronary circulation of patients with acute coronary syndromes. Circulation 2003;108: 2864-9.
32. Morange PE, Renucci JF, Charles MA, Aillaud MF, Giraud F, Grimaux M et al. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers. Thromb Haemost 2001;85:999-1003.
33. Kawaguchi A, Miyao Y, Noguchi T, Nonogi H, Yamagishi M, Miyatake K et al. Intravascular free tissue factor pathway inhibitor is inveresely correlated with HDL cholesterol and postheparin lipoprotein lipase proportional to apolipoprotein A-II. Arterioscler Thromb Vasc Biol 2000;20:251-8.
34. Matetzky S, Tani S, Kangavaris S, Dimayunga P, Yano J, Xu H et al. Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. Circulation 2000;102:602-4.
35. Holschermann H, Terhalle H, Zakel U, Maus U, Parviz B, Tillmanns H et al. Monocyte tissue factor expression is enhanced in woman who smoke and use oral contraceptives. Thromb Haemost 1999;82:1614-20.